Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2000-5-11
pubmed:abstractText
PTK787/ZK 222584 (1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine succinate) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, active in the submicromolar range. It also inhibits other class III kinases, such as the platelet-derived growth factor (PDGF) receptor beta tyrosine kinase, c-Kit, and c-Fms, but at higher concentrations. It is not active against kinases from other receptor families, such as epidermal growth factor receptor, fibroblast growth factor receptor-1, c-Met, and Tie-2, or intracellular kinases such as c-Src, c-Abl, and protein kinase C-alpha. PTK787/ZK 222584 inhibits VEGF-induced autophosphorylation of kinase insert domain-containing receptor (KDR), endothelial cell proliferation, migration, and survival in the nanomolar range in cell-based assays. In concentrations up to 1 microM, PTK787/ZK 222584 does not have any cytotoxic or antiproliferative effect on cells that do not express VEGF receptors. After oral dosing (50 mg/kg) to mice, plasma concentrations of PTK787/ZK 222584 remain above 1 microM for more than 8 h. PTK787/ZK 222584 induces dose-dependent inhibition of VEGF and PDGF-induced angiogenesis in a growth factor implant model, as well as a tumor cell-driven angiogenesis model after once-daily oral dosing (25-100 mg/kg). In the same dose range, it also inhibits the growth of several human carcinomas, grown s.c. in nude mice, as well as a murine renal carcinoma and its metastases in a syngeneic, orthotopic model. Histological examination of tumors revealed inhibition of microvessel formation in the interior of the tumor. PTK787/ZK 222584 is very well tolerated and does not impair wound healing. It also does not have any significant effects on circulating blood cells or bone marrow leukocytes as a single agent or impair hematopoetic recovery after concomitant cytotoxic anti-cancer agent challenge. This novel compound has therapeutic potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines, http://linkedlifedata.com/resource/pubmed/chemical/Phthalazines, http://linkedlifedata.com/resource/pubmed/chemical/Platelet-Derived Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor Protein-Tyrosine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vascular Endothelial..., http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/vatalanib
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2178-89
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:10786682-Humans, pubmed-meshheading:10786682-Animals, pubmed-meshheading:10786682-Mice, pubmed-meshheading:10786682-Pyridines, pubmed-meshheading:10786682-Leukocytes, pubmed-meshheading:10786682-Wound Healing, pubmed-meshheading:10786682-Kidney Neoplasms, pubmed-meshheading:10786682-Phosphorylation, pubmed-meshheading:10786682-Carcinoma, pubmed-meshheading:10786682-Hematopoiesis, pubmed-meshheading:10786682-Cell Division, pubmed-meshheading:10786682-Phthalazines, pubmed-meshheading:10786682-Neoplasm Metastasis, pubmed-meshheading:10786682-Neoplasm Transplantation, pubmed-meshheading:10786682-Tumor Cells, Cultured, pubmed-meshheading:10786682-Disease Models, Animal, pubmed-meshheading:10786682-Endothelium, Vascular, pubmed-meshheading:10786682-Bone Marrow Cells, pubmed-meshheading:10786682-Neovascularization, Pathologic, pubmed-meshheading:10786682-Dose-Response Relationship, Drug, pubmed-meshheading:10786682-Lymphokines, pubmed-meshheading:10786682-Mice, Nude, pubmed-meshheading:10786682-Platelet-Derived Growth Factor, pubmed-meshheading:10786682-Angiogenesis Inhibitors, pubmed-meshheading:10786682-Vascular Endothelial Growth Factor A, pubmed-meshheading:10786682-Vascular Endothelial Growth Factors, pubmed-meshheading:10786682-Receptor Protein-Tyrosine Kinases, pubmed-meshheading:10786682-Endothelial Growth Factors, pubmed-meshheading:10786682-Receptors, Vascular Endothelial Growth Factor, pubmed-meshheading:10786682-Receptors, Growth Factor
More...